Randomization access [Regulatives / Guidelines]

posted by bkrao  – India, 2015-08-10 12:18 (3478 d 08:55 ago) – Posting: # 15209
Views: 4,777

Thanks you.

I required few more suggestions in this regard.

If analyst knows the treatment received by the subject, then the analysis bias is open thing know?

Then the study will be a result oriented, analyst driven study, we can call. but its should not be actual outcome required by the regulatory i hope, kindly suggest.


Thanks you & Regards,
Balaga Koteswara Rao,
Cadila Pharmaceuticals Ltd.

Complete thread:

UA Flag
Activity
 Admin contact
23,381 posts in 4,914 threads, 1,663 registered users;
36 visitors (0 registered, 36 guests [including 6 identified bots]).
Forum time: 20:14 CET (Europe/Vienna)

Science is built up with facts, as a house is with stones.
But a collection of facts is no more a science
than a heap of stones is a house.    Henri Poincaré

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5